Announcements Trials
Browse Landscape

Phase

Phase NA 4Phase 2 2Phase 1 2Phase EARLY_PHASE1 1Phase 3 1Phase 2/3 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 23Carcinoma, Non-Small-Cell Lung 15Prostatic Neoplasms 14Stomach Neoplasms 12Colorectal Neoplasms 12Breast Neoplasms 12Pancreatic Neoplasms 10Leukemia, Myeloid, Acute 10Neoplasm Metastasis 9Lung Neoplasms 9Hematologic Neoplasms 9Head and Neck Neoplasms 9Carcinoma, Hepatocellular 9Squamous Cell Carcinoma of Head and Neck 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Ovarian Neoplasms 8Endometrial Neoplasms 8Myasthenia Gravis 7Melanoma 7Uterine Cervical Neoplasms 6Recurrence 6Rectal Neoplasms 6Neoplasms by Site 6Neoplasms by Histologic Type 6Lymphoma 6Leukemia 6Urinary Bladder Neoplasms 5Neoplasms, Plasma Cell 5Infections 5Colonic Neoplasms 5

Interventions

fludarabine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Recruiting × Autoimmune Diseases × Clear all
NCT06193889 2026-05-15

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

Kyverna Therapeutics

Phase 2/3 Recruiting
66 enrolled

Autoimmune Diseases, Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡